Orthofix International N.V.

Mr. Simpson became President of the U.S. entity in 2008. He joined Orthofix in 2002 as Vice President of Operations for Orthofix Inc. In 2006, Mr. Simpson was promoted to Senior Vice President of Global Operations and General Manager, Orthofix Inc. responsible for world wide manufacturing and distribution. Born in New York, raised and educated in North Texas, Mr. Simpson received his Bachelor of Science in Business and Systems Engineering from the University of Texas at Dallas. With more than 20 years of experience in a broad spectrum of industries he has held the following positions: Chief Operating Officer, Business Unit Vice President, Vice President of Operations, Vice President of Sales, Plant Manager, Director of Finance and Director of Operations. His employment history includes the following companies: Texas Instruments, Boeing, McGaw/IVAX, Mark IV Industries, Intermec and Unilever.

Ms. Pedulla joined Orthofix in June 2008 as Senior Vice President and Chief Compliance Officer. She is responsible for managing Orthofix’s domestic and international corporate compliance and government affairs programs. Ms. Pedulla was formerly Vice President, Compliance, Regulatory and Government Affairs and Associate General Counsel for Fresenius Medical Care North America. An attorney, Ms. Pedulla has more than 14 years of experience in health care regulatory compliance and is certified in health care compliance by the Health Care Compliance Association. She earned a BS in Nursing and Psychology from Boston College in 1981, a J.D. from Suffolk University in 1989, and received a Masters of Public Health degree in Health Policy and Management from Harvard University in 1990.

Mr. Vaters joined Orthofix as Executive Vice President and Chief Financial Officer in September 2008. Prior to joining Orthofix, he was the General Partner and founder of Med Opportunity Partners, a health care private equity firm. He also served as Executive Vice President, Chief Financial Officer and Head of Strategy and Corporate Development at Inamed Corporation. Mr. Vaters has over 19 years of experience in financial and strategic leadership for global companies, including Arbinet-thexchange, Premiere Technologies, Young & Rubicam, and Sequa Capital.

Mr. Hein became the Chief Financial Officer of Orthofix International N.V. on July 1, 2002. For the prior three years, Mr. Hein had been the Chief Financial Officer of Orthofix Inc., our wholly owned U.S. subsidiary. From 1996 to 1999, Mr. Hein was the Chief Financial Officer for Prime Vision Health Inc., a diversified healthcare services company. From 1988 to 1996, Mr. Hein was Vice President of Finance and Chief Financial Officer of MDT Corporation, a sterilization and hospital capital equipment company. Previously, he held financial management positions with Metheus Corporation, Memorex Corporation and Kaiser Aetna.

Mr. Kolls is Senior Vice President, General Counsel and Corporate Secretary of Orthofix International N.V. He joined the company in 2004 as Vice President, General Counsel. Before joining Orthofix, Mr. Kolls was Associate General Counsel for CSX Corporation. Mr. Kolls began his legal career as an attorney in private practice with Morgan, Lewis & Bockius. He received a B.A. from Georgetown University in 1985 and his J.D. from Georgetown University Law School in 1988.

Mr. Hewett was appointed Deputy Chairman of the Board of Directors in 2005 and has been a non-executive Director of Orthofix International N.V. since March 1992. He was the Deputy Group Chairman of Orthofix International N.V. between March 1998 and December 2000. Previously, Mr. Hewett served as the Managing Director of Caradon Plc, Chairman of the Engineering Division, Chairman and President of Caradon Inc., Caradon Plc's U.S. subsidiary and a member of the Board of Directors of Caradon Plc of England. In addition, he was responsible for Caradon Plc's worldwide human resources function and the development of its acquisition opportunities.

Mr. Milinazzo joined Orthofix International in 2005 as Chief Operating Officer and succeeded to the position of CEO the following year. Prior to joining Orthofix, Mr. Milinazzo was Vice President of Medtronic Inc.'s Vascular business, as well as, Vice President and General Manager of Medtronic's Coronary and Peripheral businesses. Prior to his time with Medtronic, Mr. Milinazzo spent 12 years as an executive with Boston Scientific Corporation in numerous roles, including Vice President of Marketing for SCIMED Europe. Mr. Milinazzo brings more than two and a half decades of experience in the management and marketing of medical device businesses, including positions with Aspect Medical Systems and American Hospital Supply. He earned a bachelor's degree, cum laude, at Boston College in 1981.

Mr. Federico joined the BioMimetic board of directors in June of 2007. Mr. Federico currently serves as a director of Orthofix International N.V., where he also served as president from 1996 to 2001, and as president and chief executive officer from 2001 to 2006. From 1985 to 1996, Mr. Federico was general manager then president of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as vice president of Dyonics, initially as director of marketing and subsequently as general manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Mr. Federico also currently serves on the boards of SRI/Surgical Express, Inc., SaluMedica, LLC and Mako Surgical Corp.

Dr. Jordan became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Dr. Jordan served as a group president at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard's global oncology business and functional responsibility for all of Bard's research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of Specialized Health Products International, Inc., Xillix Technologies Corporation and EsophyX, Inc.

Mr. Weisshaar became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Mr. Weisshaar has served as Chief Operating Officer and strategy advisor for Sensatex, Inc. Also, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickson, a medical device company, where at different times he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar earned a bachelor of science degree from MIT and an MBA from Harvard University. He currently also serves on the board of Digene Corporation.

Ms. Sainz was elected to the Orthofix International Board of Directors in 2008. She currently serves as the President and CEO of Concentric Medical. Prior to joining Concentric Medical she was President of Guidant Corporation's Cardiac Surgery Division and a member of Guidant's Management Committee prior to their acquisition by Boston Scientific. She gained significant experience in the medical device market with Lilly MDD, Guidant and Boston Scientific. Ms. Sainz holds a Bachelors and Masters Degree of Arts from the Universidad Complutense de Madrid, and a Masters Degree in International Management from AGSIM in Arizona.

Mr. Kester became a non-executive Director of Orthofix International N.V. in August 2004. Mr. Kester retired after 28 years, 18 as an audit partner, from KPMG LLP in 2002. While at KPMG, he served as the lead audit engagement partner for both public and private companies and also served four years on KPMG's National Continuous Improvement Committee. Mr. Kester earned a bachelor of science degree in mechanical engineering from Cornell University and an MBA degree from Harvard University.

Dr. von Wartburg became a non-executive Director of Orthofix International N.V. in June 2004. He is an attorney and has practiced privately in his own law firm in Basel, Switzerland since 1999, specializing in life sciences law. He has also been a professor of administrative law and public health policy at the Saint Gall Graduate School of Economics in Switzerland for 25 years. Previously, he held top management positions with Ciba Pharmaceuticals and Novartis at their headquarters in Basel, Switzerland. In addition, Mr. von Wartburg currently serves as a Director on the board of Nymox Pharmaceutical Corporation.